Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 37 of 993 for:    Heparin sodium

Heparin Dose for Radial Angiography

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01634438
Recruitment Status : Completed
First Posted : July 6, 2012
Last Update Posted : July 6, 2012
Sponsor:
Information provided by (Responsible Party):
Robert Welsh, University of Alberta

Brief Summary:
At present, coronary angiogram is usually performed either through an artery in your groin or wrist. An important limitation of the wrist approach is an increase rate of blockage of the wrist artery. It is possible that the dose of blood thinner (i.e. heparin) may decrease the risk of blockage. Early studies seem to suggest that higher dose is required to reduce the risk of this important complication. However, to date there has not been a definitive study to determine the most appropriate heparin dose for the prevention of this complication. The main goal of this study is to determine the appropriate heparin dose to prevent wrist artery blockage and to determine risk factors for developing such a complication.

Condition or disease Intervention/treatment Phase
Coronary Angiograph Drug: unfractionated heparin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Low Versus High Dose Unfractionated Heparin in Patients Undergoing Angiography Via the Radial Artery
Study Start Date : July 2008
Actual Primary Completion Date : December 2010
Actual Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners

Arm Intervention/treatment
Experimental: low dose heparin
30 units per kilogram of unfractionated heparin
Drug: unfractionated heparin
unfractionated heparin

Active Comparator: High dose heparin
70 units per kilogram of unfractionated heparin (UFH) intravenously
Drug: unfractionated heparin
unfractionated heparin




Primary Outcome Measures :
  1. radial artery occlusion [ Time Frame: one month ]
    The primary endpoint was radial artery occlusion defined as absence palpable radial artery with no flow as assessed by Doppler study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients older than 18 years of age who were referred for either urgent or elective cardiac catheterization were eligible for the study if a normal Allen's test was demonstrated

Exclusion Criteria:

  • myocardial infarction with shock,
  • ST-elevation myocardial infarction,
  • patients undergoing planned percutaneous coronary intervention, and
  • patients in whom transradial approach is contraindicated such as hemodialysis patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01634438


Locations
Layout table for location information
Canada, Alberta
Mazankowski Alberta Heart Institute
Edmonton, Alberta, Canada, T6G2B7
Sponsors and Collaborators
University of Alberta

Layout table for additonal information
Responsible Party: Robert Welsh, Principal Investigator, University of Alberta
ClinicalTrials.gov Identifier: NCT01634438     History of Changes
Other Study ID Numbers: Pro00001925
First Posted: July 6, 2012    Key Record Dates
Last Update Posted: July 6, 2012
Last Verified: July 2012

Keywords provided by Robert Welsh, University of Alberta:
coronary angiography

Additional relevant MeSH terms:
Layout table for MeSH terms
Heparin
Calcium heparin
Anticoagulants
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action